Refine by
Bronchoscopes Articles & Analysis
10 news found
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by Pharmaceuticals and Medical Devices Agency (PMDA). ...
Medical robotics innovator Noah Medical provided physicians attending the American College of Chest Physicians 2022 meeting with a preview of study data documenting its high tool in lesion rate. This data subset and demonstrations of the Galaxy System were met with excellent reviews from the interventional pulmonology community. The Galaxy System is designed to provide a fully integrated ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 2022 European Respiratory Society (ERS) International Conference. Data on the first 40 patients in the study demonstrated that treatment with the AeriSeal System successfully converted the ...
Medical robotics innovator Noah Medical today revealed that the second public demonstration of its groundbreaking Galaxy System will take place from August 11th - 13th at the American Association for Bronchology and Interventional Pulmonology (AABIP) annual meeting in Nashville, TN. The Galaxy System is the only fully integrated solution for navigated bronchoscopy, designed to dramatically ...
208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic therapy by 45%, shortened inappropriate antibiotic therapy by 39 hours, and reduced overall antibiotic therapy duration by 22.5% Unyvero results combined with antibiotic stewardship are efficient and safe in decreasing time on inappropriate ...
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced that the U.S. Patent and ...
The company, founded by medical robotics entrepreneur Jian Zhang, will use these state-of-the-art facilities to pursue disruptive new medical robotics indications left unaddressed by current platforms. “We envision a world in which next generation medical robots help diagnose disease and treat patients early to ensure minimal hospital stays and quick recoveries,” said Zhang, Noah ...
The American Lung Association recently released its 2021 State of Lung Cancer report. Lung cancer is the leading cause of cancer deaths worldwide because the disease is often diagnosed at the late stages. Early diagnosis of lung nodules can help patients get treatment sooner and improve long-term survival rates. Auris is committed to fighting this deadly disease by helping physicians diagnose ...
The Monarch Platform was featured on the cover of the March-April 2019 issue of Oncology Issues. The journal, which is the official journal of the Association of Community Cancer Centers, was created for multidisciplinary oncology teams to provide information on a range of topics in cancer care. In the March-April issue of the journal, the Monarch Platform was featured in an article titled ...
Innovation begins when there is a need for something better. The Monarch™ Platform has been named a 2019 Edison Award finalist in the medical/dental category. The annual award competition honors excellence in new product and service development, marketing, human-centered design and innovation. Since its inception in 1987, the Edison Awards have sought to foster innovation by recognizing ...